PLASMA-PROTEIN BINDING OF RISPERIDONE AND ITS DISTRIBUTION IN BLOOD

被引:84
作者
MANNENS, G
MEULDERMANS, W
SNOECK, E
HEYKANTS, J
机构
[1] Department of Drug Metabolism and Pharmacokinetics, Janssen Research Foundation, Beerse, B-2340
关键词
ANTIPSYCHOTIC; PLASMA PROTEIN BINDING; DISTRIBUTION IN BLOOD; INTERACTION; DISPLACEMENT; RISPERIDONE; 9-HYDROXY-RISPERIDONE; ACTIVE METABOLITE; ALBUMIN; ALPHA(1)-ACID GLYCOPROTEIN;
D O I
10.1007/BF02244986
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The plasma protein binding of the new antipsychotic risperidone and of its active metabolite 9-hydroxy-risperidone was studied in vitro by equilibrium dialysis. Risperidone was 90.0% bound in human plasma, 88.2% in rat plasma and 91.7% in dog plasma. The protein binding of 9-hydroxy-risperidone was lower and averaged 77.4% in human plasma, 74.7% in rat plasma and 79.7% in dog plasma. In human plasma, the protein binding of risperidone was independent of the drug concentration up to 200 ng/ml. The binding of risperidone increased at higher pH values. Risperidone was bound to both albumin and alpha(1)-acid glycoprotein. The plasma protein binding of risperidone and 9-hydroxy-risperidone in the elderly was not significantly different from that in young subjects. Plasma protein binding differences between patients with hepatic or renal impairment and healthy subjects were either not significant or rather small. The blood to plasma concentration ratio of risperidone averaged 0.67 in man, 0.51 in dogs and 0.78 in rats. Displacement interactions of risperidone and 9-hydroxy-risperidone with other drugs were minimal.
引用
收藏
页码:566 / 572
页数:7
相关论文
共 17 条
  • [1] RISPERIDONE VERSUS HALOPERIDOL IN THE TREATMENT OF CHRONIC-SCHIZOPHRENIC INPATIENTS - A MULTICENTER DOUBLE-BLIND COMPARATIVE-STUDY
    CLAUS, A
    BOLLEN, J
    DECUYPER, H
    ENEMAN, M
    MALFROID, M
    PEUSKENS, J
    HEYLEN, S
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1992, 85 (04) : 295 - 305
  • [2] ALPHA-1-ACID GLYCOPROTEIN CONCENTRATION AND SERUM-PROTEIN BINDING OF CARBAMAZEPINE AND CARBAMAZEPINE-10,11 EPOXIDE IN CHILDREN WITH EPILEPSY
    CONTIN, M
    RIVA, R
    ALBANI, F
    PERUCCA, E
    LAMONTANARA, G
    BARUZZI, A
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 29 (02) : 211 - 214
  • [3] PILOT CLINICAL INVESTIGATION OF RISPERIDONE IN THE TREATMENT OF PSYCHOTIC-PATIENTS
    GELDERS, YG
    HEYLEN, SLE
    VANDENBUSSCHE, G
    REYNTJENS, AJM
    JANSSEN, PAJ
    [J]. PHARMACOPSYCHIATRY, 1990, 23 (05) : 206 - 211
  • [4] PHARMACOKINETICS OF THE NOVEL ANTIPSYCHOTIC AGENT RISPERIDONE AND THE PROLACTIN RESPONSE IN HEALTHY-SUBJECTS
    HUANG, ML
    VANPEER, A
    WOESTENBORGHS, R
    DECOSTER, R
    HEYKANTS, J
    JANSEN, AAI
    ZYLICZ, Z
    VISSCHER, HW
    JONKMAN, JHG
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) : 257 - 268
  • [5] JANSSEN PAJ, 1988, J PHARMACOL EXP THER, V244, P685
  • [6] KREMER JMH, 1988, PHARMACOL REV, V40, P1
  • [7] IMIPRAMINE SERUM-PROTEIN BINDING IN HEALTHY-SUBJECTS
    KRISTENSEN, CB
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 34 (05) : 689 - 694
  • [8] LEYSEN JE, 1988, J PHARMACOL EXP THER, V247, P661
  • [9] PROTEIN-BINDING DRUG DISPLACEMENT INTERACTIONS - FACT OR FICTION
    MACKICHAN, JJ
    [J]. CLINICAL PHARMACOKINETICS, 1989, 16 (02) : 65 - 73
  • [10] MANNENS G, 1993, DRUG METAB DISPOS, V21, P1134